Clinical Trials Logo

Leukemia, Monocytic, Acute clinical trials

View clinical trials related to Leukemia, Monocytic, Acute.

Filter by:

NCT ID: NCT05566054 Recruiting - Newly Diagnosed Clinical Trials

Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia

Start date: March 1, 2022
Phase: Phase 2
Study type: Interventional

This study is to investigate the therapeutic efficacy and side effect of venetoclax, azacytidine combined with chidamide for newly diagnosed acute monocytic leukemia patients that are ineligible for intensive chemotherapy

NCT ID: NCT05313958 Recruiting - Pediatric AML Clinical Trials

Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children

SCCLG-M5
Start date: December 1, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

This is a multicenter, single arm, prospective, intervention trial. Since cladribine can enhance the biological activity and self-protection of cytarabine, giving cladribine and cytarabine together may kill more cancer cells. 10 centers from South China Childhood Leukaemia Collaborative Group carry out the SCCLG-M5-2022 regimen including two courses of CLAG(cladribine, darubicin and cytarabine) in the induction period for the treatment of newly dignosed acute monocytic leukemia (M5). The targeted drugs sorafenib is used for FLT3 positive acute monocytic leukemia to inhibit the serine / threonine kinase activity of FLT3.

NCT ID: NCT02527174 Withdrawn - Clinical trials for Leukemia, Myeloid, Acute

A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia

VIAC
Start date: November 2016
Phase: Phase 1
Study type: Interventional

This is a Phase I clinical trial to determine the maximum tolerated dose (MTD) of the polo-like kinase-1 inhibitor volasertib which can be safely combined with idarubicin plus cytarabine induction chemotherapy for previously untreated patients with acute myeloid leukemia. (AML).

NCT ID: NCT02144675 Completed - Clinical trials for Recurrent Adult Acute Myeloid Leukemia

Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia

Start date: January 2009
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well choline magnesium trisalicylate with idarubicin and cytarabine works in treating patients with acute myeloid leukemia. Drugs used in chemotherapy, such as choline magnesium trisalicylate, idarubicin, and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. It is not yet know whether choline magnesium trisalicylate and combination chemotherapy is more effective than combination chemotherapy alone in treating patients with acute myeloid leukemia.

NCT ID: NCT02105116 Terminated - Clinical trials for Recurrent Adult Acute Myeloid Leukemia

AML Therapy With Irradiated Allogeneic Cells

Start date: February 2014
Phase: N/A
Study type: Interventional

This pilot clinical trial studies if cells donated by a close genetic relative can help maintain acute myeloid leukemia (AML) complete remission (CR). Eligible patients will receive a standard induction chemotherapy. If a complete remission results they will receive irradiated allogeneic cells from a HLA haploidentical relative. Only patients who obtain a CR after the standard induction chemotherapy are eligible for the experimental therapy (irradiated haploidentical cells).

NCT ID: NCT02085408 Active, not recruiting - Clinical trials for Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities

Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Start date: February 4, 2011
Phase: Phase 3
Study type: Interventional

This randomized phase III trial studies clofarabine to see how well it works compared with daunorubicin hydrochloride and cytarabine when followed by decitabine or observation in treating older patients with newly diagnosed acute myeloid leukemia. Drugs used in chemotherapy, such as clofarabine, daunorubicin hydrochloride, cytarabine, and decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. It is not yet known which chemotherapy regimen is more effective in treating acute myeloid leukemia.

NCT ID: NCT02071901 Active, not recruiting - Clinical trials for Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities

Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy

Start date: August 14, 2014
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well eltrombopag olamine works in improving the recovery of platelet counts in older patients with Acute Myeloid Leukemia (AML) undergoing induction (the first treatment given for a disease) chemotherapy. Platelet counts recover more slowly in older patients, leading to risk of complications and the delay of post-remission therapy. Eltrombopag olamine may cause the body to make platelets after chemotherapy.

NCT ID: NCT02049801 Terminated - Clinical trials for Recurrent Adult Acute Myeloid Leukemia

MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Start date: December 2014
Phase: Phase 1
Study type: Interventional

This phase I trial studies the MEK inhibitor MEK162 to see if it is safe in patients when combined with idarubicin and cytarabine. MEK inhibitor MEK162 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as idarubicin and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving MEK inhibitor MEK162, cytarabine, and idarubicin may be an effective treatment for acute myeloid leukemia.

NCT ID: NCT02030405 Terminated - Clinical trials for Recurrent Adult Acute Myeloid Leukemia

Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Start date: March 2014
Phase: Phase 2
Study type: Interventional

This phase 2 trial studies how well ixazomib(MLN9708) works in treating study participants with relapsed or refractory acute myeloid leukemia. Ixazomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT02029417 Terminated - Clinical trials for Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities

Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Start date: July 2014
Phase: Phase 2
Study type: Interventional

This phase II trial studies the side effects and how well omacetaxine mepesuccinate, cytarabine, and decitabine work in treating older patients with newly diagnosed acute myeloid leukemia. Omacetaxine mepesuccinate, cytarabine, and decitabine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.